As the results of ongoing studies with novel oral SERDs (as a single agent or in combination with other targeted therapies), the landscape of endocrine-therapy-based treatment for ER-positive HER2-negative breast cancer may continue to evolve in the next few years. This evidence concerns the gene ESR1 and breast carcinoma.